Efficacy and safety of trifluridine/tipiracil (TAS-102) in patients with metastatic colorectal cancer: a systematic review and meta-analysis.

Author: BaoWenguang, BinYehong, HuangFengxiang, LvXiaoping, WangMan, YangHaiyan, ZhouShengsheng

Paper Details 
Original Abstract of the Article :
OBJECTIVES: The purpose of this meta-analysis is to evaluate the efficacy and safety of TAS-102 in treating metastatic colorectal cancer (mCRC) using the most recent data available. METHODS: The literature on the efficacy and safety of TAS-102 versus placebo and/or best supportive care (BSC) in mCR...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1007/s12094-023-03268-5

データ提供:米国国立医学図書館(NLM)

TAS-102: A Hopeful Treatment for Metastatic Colorectal Cancer

The world of oncology is a vast desert, and researchers are constantly searching for oases of hope for patients battling metastatic colorectal cancer (mCRC). This study, like a well-placed oasis, explores the efficacy and safety of TAS-102, a drug like a camel's hump, providing a source of nourishment in the fight against cancer.

The study, conducted through a systematic review and meta-analysis, aimed to evaluate the effectiveness and safety of TAS-102 compared to placebo and best supportive care (BSC). This was achieved through a meticulous examination of recent data, like a seasoned traveler meticulously reading ancient maps.

The researchers discovered that TAS-102 treatment led to prolonged overall survival (OS), progression-free survival (PFS), time to treatment failure (TTF), and a higher disease control rate (DCR) in patients with mCRC compared to placebo and/or BSC. Notably, TAS-102 demonstrated a significant improvement in OS and PFS even in patients with KRAS wild-type and KRAS mutant-type mCRC, like a camel navigating a harsh desert, adapting to diverse landscapes.

A New Oasis in Cancer Treatment

The findings suggest that TAS-102 offers a promising therapeutic option for patients with mCRC whose standard therapy has failed. This new oasis provides hope for a prolonged and more comfortable journey through their cancer treatment.

A Balanced Approach to Treatment

The study emphasizes the importance of balancing efficacy with safety. TAS-102, like a wise traveler choosing a route, has demonstrated effectiveness without compromising safety. This is particularly important in cancer treatment, where the journey can be arduous and the potential side effects daunting.

Dr. Camel's Conclusion

TAS-102 emerges as a valuable addition to the fight against metastatic colorectal cancer. Its ability to enhance prognosis while maintaining acceptable safety makes it a promising treatment option for this challenging disease. It's like discovering a new oasis in the desert, providing a lifeline for those in need.

Date :
  1. Date Completed n.d.
  2. Date Revised 2023-08-03
Further Info :

Pubmed ID

37414979

DOI: Digital Object Identifier

10.1007/s12094-023-03268-5

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.